Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypersensitivity, Immediate

ClinicalTrials.gov lists 8,524 trials for Hypersensitivity, Immediate or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 342.

MeSH D006969 Immune System Diseases C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 751 Phase 1/2 Phase 1/2 179 Phase 2 Phase 2 1,328 Phase 2/3 Phase 2/3 112 Phase 3 Phase 3 1,262 Phase 4 Phase 4 830 Not applicable Not applicable 1,990 Observational Observational 2,053 Phase 1 Phase 1 751 Phase 1/2 Phase 1/2 179 Phase 2 Phase 2 1,328 Phase 2/3 Phase 2/3 112 Phase 3 Phase 3 1,262 Phase 4 Phase 4 830 Not applicable Not applicable 1,990 Observational Observational 2,053

Trials per phase

1 more section with rows

81 of the 8,524 trials are tagged with Hypersensitivity, Immediate itself; the rest are tagged with a narrower condition beneath it.

Get the Hypersensitivity, Immediate report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypersensitivity, Immediate trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 433

1990: 9 trials (Observational 7, Not applicable 1, Phase 3 1) 1991: 5 trials (Observational 4, Phase 3 1) 1992: 7 trials (Observational 5, Not applicable 1, Phase 4 1) 1993: 6 trials (Observational 3, Phase 4 1, Phase 3 2) 1994: 9 trials (Observational 4, Not applicable 2, Phase 3 3) 1995: 7 trials (Observational 5, Phase 3 2) 1996: 12 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 1) 1997: 12 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 1) 1998: 20 trials (Observational 6, Not applicable 3, Phase 4 4, Phase 3 6, Phase 2 1) 1999: 33 trials (Observational 17, Not applicable 5, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 3) 2000: 38 trials (Observational 14, Not applicable 6, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 1, Phase 1/2 2) 2001: 54 trials (Observational 12, Not applicable 14, Phase 4 6, Phase 3 15, Phase 2 5, Phase 1/2 1, Phase 1 1) 2002: 98 trials (Observational 11, Not applicable 14, Phase 4 26, Phase 3 32, Phase 2 13, Phase 1/2 1, Phase 1 1) 2003: 130 trials (Observational 11, Not applicable 27, Phase 4 32, Phase 3 43, Phase 2/3 1, Phase 2 15, Phase 1/2 1) 2004: 182 trials (Observational 26, Not applicable 27, Phase 4 40, Phase 3 58, Phase 2/3 4, Phase 2 18, Phase 1/2 1, Phase 1 8) 2005: 250 trials (Observational 45, Not applicable 34, Phase 4 40, Phase 3 65, Phase 2/3 6, Phase 2 36, Phase 1/2 4, Phase 1 20) 2006: 265 trials (Observational 39, Not applicable 43, Phase 4 51, Phase 3 53, Phase 2/3 9, Phase 2 43, Phase 1/2 9, Phase 1 18) 2007: 319 trials (Observational 69, Not applicable 42, Phase 4 65, Phase 3 57, Phase 2/3 3, Phase 2 52, Phase 1/2 4, Phase 1 27) 2008: 327 trials (Observational 66, Not applicable 60, Phase 4 42, Phase 3 40, Phase 2/3 3, Phase 2 71, Phase 1/2 11, Phase 1 34) 2009: 354 trials (Observational 84, Not applicable 69, Phase 4 45, Phase 3 34, Phase 2/3 5, Phase 2 79, Phase 1/2 8, Phase 1 30) 2010: 359 trials (Observational 64, Not applicable 61, Phase 4 39, Phase 3 45, Phase 2/3 13, Phase 2 83, Phase 1/2 11, Phase 1 43) 2011: 356 trials (Observational 91, Not applicable 75, Phase 4 35, Phase 3 55, Phase 2/3 4, Phase 2 56, Phase 1/2 7, Phase 1 33) 2012: 374 trials (Observational 76, Not applicable 91, Phase 4 23, Phase 3 52, Phase 2/3 6, Phase 2 83, Phase 1/2 12, Phase 1 31) 2013: 311 trials (Observational 52, Not applicable 71, Phase 4 31, Phase 3 42, Phase 2/3 6, Phase 2 71, Phase 1/2 8, Phase 1 30) 2014: 320 trials (Observational 56, Not applicable 86, Phase 4 27, Phase 3 57, Phase 2/3 5, Phase 2 46, Phase 1/2 5, Phase 1 38) 2015: 347 trials (Observational 80, Not applicable 94, Phase 4 27, Phase 3 47, Phase 2/3 6, Phase 2 58, Phase 1/2 5, Phase 1 30) 2016: 326 trials (Observational 74, Not applicable 93, Phase 4 26, Phase 3 43, Phase 2/3 5, Phase 2 43, Phase 1/2 5, Phase 1 37) 2017: 351 trials (Observational 93, Not applicable 99, Phase 4 22, Phase 3 42, Phase 2/3 4, Phase 2 50, Phase 1/2 6, Phase 1 35) 2018: 372 trials (Observational 101, Not applicable 87, Phase 4 29, Phase 3 70, Phase 2/3 1, Phase 2 52, Phase 1/2 5, Phase 1 27) 2019: 381 trials (Observational 105, Not applicable 98, Phase 4 26, Phase 3 46, Phase 2/3 1, Phase 2 55, Phase 1/2 7, Phase 1 43) 2020: 322 trials (Observational 113, Not applicable 70, Phase 4 23, Phase 3 32, Phase 2/3 6, Phase 2 44, Phase 1/2 9, Phase 1 25) 2021: 433 trials (Observational 149, Not applicable 96, Phase 4 30, Phase 3 48, Phase 2/3 5, Phase 2 53, Phase 1/2 12, Phase 1 40) 2022: 422 trials (Observational 115, Not applicable 117, Phase 4 24, Phase 3 55, Phase 2/3 5, Phase 2 52, Phase 1/2 15, Phase 1 39) 2023: 429 trials (Observational 125, Not applicable 124, Phase 4 23, Phase 3 49, Phase 2/3 3, Phase 2 55, Phase 1/2 10, Phase 1 40) 2024: 429 trials (Observational 113, Not applicable 139, Phase 4 31, Phase 3 60, Phase 2/3 1, Phase 2 44, Phase 1/2 4, Phase 1 37) 2025: 417 trials (Observational 109, Not applicable 116, Phase 4 18, Phase 3 37, Phase 2/3 6, Phase 2 77, Phase 1/2 7, Phase 1 47)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 347
2025 417
2024 429
2023 429
2022 422
2021 433
2020 322
2019 381
2018 372
2017 351

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 410 trials starting in 2026 and about 410 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 514 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 5,937 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypersensitivity, Immediate trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 751
Phase 1/2 179
Phase 2 1,328
Phase 2/3 112
Phase 3 1,262
Phase 4 830
Not applicable 1,990
Observational 2,053
Expanded access 19

How many Hypersensitivity, Immediate trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 256
Recruiting 662
Enrolling by invitation 57
Active, not recruiting 250
Available 9

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypersensitivity, Immediate trials? (12)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 342
GlaxoSmithKline 339
Novartis Pharmaceuticals 151
Organon and Co 149
National Institute of Allergy and Infectious Diseases (NIAID) 101

Showing 5 of 12 sponsors.

Start your 14-day trial Email me all 12 sponsors as a PDF

Which drugs are being tested for Hypersensitivity, Immediate? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
OPN-375 139
Montelukast 136
Albuterol 56
LYR-210 37

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Drug: Omalizumab 145
Dupilumab/Dupixent 136
Budesonide EC 88
Fluticasone foroate 53
Mepolizumab SC 52

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypersensitivity, Immediate trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Invasive cancer of any type 4,851 1
Asthma 3,173 299
Major cardiovascular event 2,415 1
Gastrointestinal bleeding 2,232 1
Pneumonia 1,045 238

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypersensitivity, Immediate? (279)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Beta-lactam hypersensitivity diagnosis in ambulatory and hospitalized settings require different approaches. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023 Yes
Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis. Archivos de bronconeumologia 2023 Yes
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. The European respiratory journal 2023 Yes
Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2022 Yes
Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study. BMC pulmonary medicine 2022 Yes

Showing 5 of 279 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (10)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages